Education
About Us
Working with TipRanks
Follow Us
NervGen Pharma (TSE:NGEN)
:NGEN
Total Valuation
NervGen Pharma has a market cap or net worth of C$643.12M. The enterprise value is C$231.86M.
Market CapC$643.12M
Enterprise ValueC$231.86M
Share Statistics
NervGen Pharma has 79,593,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79,593,760
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NervGen Pharma’s return on equity (ROE) is -9.32 and return on invested capital (ROIC) is -897.01%.
Return on Equity (ROE)-9.32
Return on Assets (ROA)-1.23
Return on Invested Capital (ROIC)-897.01%
Return on Capital Employed (ROCE)-9.64
Revenue Per Employee0.00
Profits Per Employee-2.18M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NervGen Pharma is ―. NervGen Pharma’s PEG ratio is 1.67.
PE Ratio―
PS Ratio0.00
PB Ratio82.04
Price to Fair Value82.04
Price to FCF-12.55
Price to Operating Cash Flow-24.52
PEG Ratio1.67
Income Statement
In the last 12 months, NervGen Pharma had revenue of 0.00 and earned -24.01M in profits. Earnings per share was -0.36.
Revenue0.00
Gross Profit-83.80K
Operating Income-24.93M
Pretax Income-24.01M
Net Income-24.01M
EBITDA-23.92M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -16.76M and capital expenditures 0.00, giving a free cash flow of -16.76M billion.
Operating Cash Flow-16.76M
Free Cash Flow-16.76M
Free Cash Flow per Share-0.21
Dividends & Yields
NervGen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change162.34%
50-Day Moving Average5.26
200-Day Moving Average4.03
Relative Strength Index (RSI)75.14
Average Volume (3m)93.83K
Important Dates
NervGen Pharma upcoming earnings date is Apr 2, 2026, After Close (Confirmed).
Last Earnings DateNov 24, 2025
Next Earnings DateApr 2, 2026
Ex-Dividend Date―
Financial Position
NervGen Pharma as a current ratio of 1.12, with Debt / Equity ratio of -6.28%
Current Ratio1.12
Quick Ratio1.12
Debt to Market Cap<0.01
Net Debt to EBITDA0.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NervGen Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NervGen Pharma EV to EBITDA ratio is -8.12, with an EV/FCF ratio of -11.53.
EV to Sales0.00
EV to EBITDA-8.12
EV to Free Cash Flow-11.53
EV to Operating Cash Flow-11.53
Balance Sheet
NervGen Pharma has C$11.40M in cash and marketable securities with C$57.71K in debt, giving a net cash position of C$11.36M billion.
Cash & Marketable SecuritiesC$11.40M
Total DebtC$57.71K
Net CashC$11.36M
Net Cash Per ShareC$0.14
Tangible Book Value Per ShareC$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NervGen Pharma is C$10.72, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$10.72
Price Target Upside32.63% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast2.22%